{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-311286","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.348295+00:00","generated_at":"2026-06-28T17:12:03.609903+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ResMed reports Q1 FY2022 revenue $904M (+20% YoY), diluted EPS $1.39, non-GAAP EPS $1.51","bullets":["Revenue $904.0M, up 20% YoY (19% constant currency); all segments grew double-digits.","Diluted EPS $1.39 (+14% YoY); non-GAAP diluted EPS $1.51 (+19% YoY).","Income from operations $261.9M (+21%); non-GAAP operating profit $280.7M (+18%).","Board declared quarterly cash dividend of $0.42/share, payable Dec 16, 2021, record Nov 11.","CEO cited strong demand but ongoing supply chain constraints limiting electronic components."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-311286","json":"https://secwatch.observer/filing/0001193125-21-311286.json","markdown":"https://secwatch.observer/filing/0001193125-21-311286.md","text":"https://secwatch.observer/filing/0001193125-21-311286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312521311286/0001193125-21-311286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312521311286/d801447d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:12:03.609903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}